Business
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
Expects to Begin Dosing in a First-in-Human Study of EDP-235, an Oral 3CL Protease Inhibitor Specifically Designed for the Treatment of COVID-19, This Month
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nExpects to Begin Dosing in a First-in-Human Study of EDP-235, an Oral 3CL Protease Inhibitor Specifically Designed for the Treatment of COVID-19, This Month\n\n\nCompleted Enrollment in RSVP, a Phase 2b Study of EDP-938 in Adults With Community-Acquired Respiratory Syncytial Virus (RSV); Expects Topline Data in the Second Quarter of 2022\n\n\nPlans to Initiate a Phase 1 Study of EDP-323, an RSV L-Protein Inhibitor, in the Second Half of 2022\n\n\nRoyalty Revenue for the Quarter was $27.6 Million\n\n\n WATERTOWN, Mass.--(BUSINESS WIRE)--\nEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal first quarter ended December 31, 2021.\n\n“We are excited to begin dosing subjects this month with EDP-235, our SARS-CoV-2 3CL protease inhibitor specifically designed as a once-daily, orally-dosed treatment for COVID-19. As the COVID-19 pandemic continues, demand for a convenient, once-daily therapeutic is stronger than ever, and we look forward to advancing EDP-235 as a COVID-19 treatment option based on its potential best-in-class preclinical profile,” said Jay R. Luly Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “Building on our respiratory virus portfolio, we also made significant progress in our RSV programs. Last quarter we completed enrollment in RSVP, our Phase 2b Study of EDP-938 in adults with community-acquired RSV, and we are eager to report topline data next quarter. Additionally, last month, we were pleased to introduce EDP-323, an RSV L-protein inhibitor that can be used alone or in combination with EDP-938 to potentially broaden the addressable patient populations or their treatment windows, and we plan to initiate a Phase 1 study of EDP-323 in the second half of 2022. Importantly, we remain committed to developing a functional cure for chronic hepatitis B virus patients with EDP-514, our lead core inhibitor, in combination with other mechanisms. We believe that a potent core inhibitor such as EDP-514 will be an important component of a successful combination treatment regimen.”\n\nFiscal First Quarter Ended December 31, 2021 Financial Results\n\nTotal revenue for the three months ended December 31, 2021 was $27.6 million and consisted e...